ISSN 1866-8836
Клеточная терапия и трансплантация

Integration of leukemia research in Europe: the paradigm CML

R. Hehlmann, S. Saußele

Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Wiesbadener Str. 7-11, 68305 Mannheim, Germany

Prof. Dr. Dr. h.c. R. Hehlmann, Medizinische Fakultät Mannheim der Universität Heidelberg, Pettenkoferstr. 22, 68169 Mannheim, Germany
Phone: +49 (0) 621-383-69-31, fax: +49 (0)621-383-69-32, E-mail:
doi 10.3205/ctt-2008-en-000015.01
Submitted 29 September 2008
Accepted 10 October 2008
Published 02 December 2008


Presented at the 2nd Raissa Gorbacheva Memorial Symposium in St. Petersburg, Russia, on 20 September 2008.

Leukemias are rare diseases, the investigation into which requires multicenter activities, study groups and networking. The ELN integrates leukemia research and trial groups across Europe. Progress with CML continues to promote European integration (EUTOS for CML). Median survival with CML is now expected at 25 years. The main treatment options for CML are TK inhibition and allo-SCT. Treatment optimization trials are ongoing worldwide. Looking at the speed of current progress, the prospects for a cure of CML, and possibly other forms of leukemia, are good.


Chronic myeloid leukemia, bcr-abl, tyrosine kinase, inhibitors, clinical response, comparative trials, european leukemia network


One of the main challenges of current leukemia research is the rarity of leukemias. The incidence of the various leukemias per 100,000 population/year range between around 1 (ALL) and 3-4 (CLL). The challenge is met by collaboration within cooperative groups and networks. Integration of leukemia research in Europe has been achieved to a high degree by cooperation at the level of national leukemia study groups, notably CML study groups, and by networking on national and European levels. The German CML Study Group (founded in 1982) was one of the cofounders of the European Investigators on CML Group (EI-CML), which was initiated by S. Tura, Bologna, in 1992. Fig. 1 shows the distribution of national CML study groups in Europe. On a German level, the German CML Study Group, together with other German leukemia study groups, started the German Competence Network “Akute und chronische Leukämien” (KNL) in 1997, which was funded by the German Ministry for Education and Research in 1999. The KNL, which combines all leukemia study groups in one country and the EI-CML, which combines all European groups cooperating on one leukemia, started the European LeukemiaNet (ELN) in 2002. This has been funded by the European Commission (EC) as a Network of Excellence (NoE) from 2004 onwards. Fig. 2 shows a flow diagram of the integration of leukemia research in Europe.



The groups forming the ELN all have convincing records in promoting leukemia research and improving survival for patients with leukemia. An example is the German CML Study Group, with its 600 participants in about 300 centers (Fig. 3). The group has conducted 5 major randomized studies over the past 25 years, which has improved survival of CML patients in Germany significantly from a median survival time of 3-4 years in 1983 to an expected median of about 25 years in 2008. Fig. 4 shows the improvement of survival in the trials of the German CML Study Group up to the present time. The current 5-year-survival of 93% in CML Study IV is better than that reported by any other study group.



The ELN, representing a collaboration of European leukemia study groups and their interdisciplinary partner groups, currently comprises 147 centers in 28 countries (Fig. 5), and involves about 1,000 physicians and scientists. The participating leukemia study groups are caring for some 10,000 leukemia patients across Europe. Cooperation is amongst 95 national leukemia study groups and 102 interdisciplinary partner groups as depicted in Figs. 6 and 7.




The goals of the ELN are to strengthen scientific and technological excellence in research and treatment of leukemias, promote clinical trials, prepare guidelines, and spread excellence. The success of the European approach in improving research and patient outcome is well illustrated by the paradigm chronic myeloid leukemia (CML).

Paradigm CML
1847: Term “Leukämie” coined
1960: Philadelphia chromosome discovered
1985: Fusion gene BCR-ABL detected
1990: BCR-ABL induces leukemia in mice
1998: BCR-ABL TK inhibitor imatinib in phase I
2008: Median survival (expected) 25 years

The term “leukemia” was coined  in 1847 [1]  to describe patients with what was later recognized to be CML. The name was later given to the whole group of leukemias. CML became the first neoplastic disease regularly associated with a chromosomal aberration, the Philadelphia-translocation (1960) [2]. CML also became the first neoplastic disease in which the molecular pathogenesis was elucidated. In 1985, the fusion gene BCR-ABL coding for a BCR-ABL fusion tyrosine kinase (TK) was detected [3], and in 1990 it was shown that BCR-ABL can induce leukemia in mice [4, 5]. This finding prompted experiments to inhibit BCR-ABL TK via specific inhibitors [6]. In 1998, a phase I trial with the TK inhibitor imatinib was started. The outcome was striking. Even patients with advanced disease achieved cytogenetic remissions [7]. This success was achieved by the cooperation of academic research with drug development by the pharmaceutical industry. The development of a “targeted” therapy for CML would not have been possible without close cooperation among all players in the field (trial groups, groups in cytogenetic and molecular research, pharmaceutical industry, etc.)

The molecular elucidation of CML pathogenesis relied heavily on earlier research with retroviruses and oncogenes. In this research an acute leukemia-inducing murine retrovirus, termed Abelson Virus, was found to contain a 5.6 kb long cellular RNA-sequence which, due to its oncogenic potential, was termed an “ABL oncogene”. In the human genome, ABL is located on chromosome 9, from where part of it is translocated to chromosome 22 in exchange for a larger piece of chromosome 22 called the “breakpoint cluster region” (BCR), which is in turn translocated to chromosome 9 adjacent to the remaining ABL sequences. According to the locations of the breakpoint and the size of the resulting fusion proteins, 3 sizes of proteins can be identified: a p210 BCR-ABL protein, which is regularly associated with CML; a p190 BCR-ABL protein, which is predominantly found in ALL; and a p230 BCR-ABL protein, which is found in a rare form of CML called “chronic neutrophilic leukemia” or CNL. The BCR-ABL proteins with the locations of the TKs are depicted in Fig. 8. Due to these findings, CML became the first neoplastic disease in which elucidation of pathogenesis led to a rationally designed therapy targeted at the cause of the disease. The 6-year-survival rate with imatinib in the so-called “IRIS trial”, a randomized comparison of imatinib with the former standard therapy interferon α (IFN), currently stands at 88%, with a complete cytogenetic remission rate of 82% [8]. The development of survival in CML in various trials during the years 1979-2008 is depicted in Fig. 9. Imatinib has been shown to be superior to IFN, and the survival rate with imatinib is better than with any other therapy.



The problem with current imatinib therapy is that – due to various reasons – within 6 years about 37% of patients do not respond satisfactorily or at all to imatinib, or are suspended from treatment. This is in part due to resistance mutations [9], but also to disease evolution or adverse effects. Therefore various treatment optimization trials were started to improve imatinib therapy either by combination with other agents such as IFN or araC, or by increasing the imatinib dosage. One of these studies, the German 5-arm randomized CML Study IV (GEIST), started in 2002 and has currently recruited more than 1200 patients (Fig. 10). With a survival rate of 94% in the primary imatinib arms, it is more successful than in any other current study. After 36 months, rates of major cytogenetic responses in the primary imatinib arms are close to 90%, of complete cytogenetic remissions more than 85%, and of major molecular remissions around 79%.


Once blast crisis (BC) develops, prognosis remains poor. Median survival of 605 patients with BC in the German CML Studies I, II, III and IIIA (recruitment 1983–2003) is 4 months (Fig. 11). Only 21 patients remain alive; 15 of them after transplantation.


One study of the German CML Study Group (CML-Study III) has evaluated the role of stem cell transplantation by randomized comparison with best available drug treatment [10]. After a median observation time of more than 8 years with an observation time up to 11 years, a significant survival advantage for best available drug treatment was determined (Fig. 12). It is concluded that drug treatment now should be first line therapy for CML. Stem cell transplantation remains an important second line option and may be given first line on an individual basis.


Various second line TK inhibitors are currently in various phases of evaluation. Dasatinib, which is 325 times more potent than imatinib, has been shown to have an 18-month-survival outcome of  96% in imatinib resistant or intolerant patients [11, 12]. In the chronic phase, 100 mg dasatinib once a day has been shown to be equally effective and less toxic than 2x70 mg. Dasatinib has remarkable activity in BC with a 2-year-survival of 38% in myeloid and 26% in lymphoid BC. A relevant property of dasatinib is its ability to pass the blood/brain barrier [13]. Nilotinib is about 30 times more potent than imatinib, and also has good activity in blast crisis with a 12-month-survival rate of 42% [14].

In conclusion, dasatinib and nilotinib have hematologic and cytogenetic efficacy in imatinib resistant and intolerant CML in all phases, and are active against all BCR-ABL TK-mutations except T315I. Main toxicities are cytopenias and pleural effusions (dasatinib). After dasatinib and nilotinib treatment new resistance mutations have been observed. For mutation I255V/K both drugs are not sufficiently efficacious at the standard dose, and a dose increase is recommended. In F317L, nilotinib is efficacious, in Y253H dasatinib. Agents in clinical studies include dasatinib and nilotinib in randomized evaluation for first line therapy; bosutinib, INNO406, histone deacetylase inhibitors, aurora kinase inhibitors and others, alone or in combination with other agents, in phase I and II and more in preclinical evaluation.

A major goal of the ELN is the development of guidelines for diagnosis and treatment in leukemias. CML management recommendations were published in 2006 [15], APL guidelines in 2008 [16], an update for CML is planned for 2009, and AML guidelines are in preparation. The current CML recommendations are summarized in the algorithm in Fig. 13 [17]. In case of intolerance, toxicity or pregnancy IFN is recommended, in case of imatinib failure or resistance, 2nd generation TK inhibitors or allo-SCT. In the case of suboptimal response patients should be observed closely, and an increase of imatinib dosage should be attempted. If the treatment effect is less than expected or the toxicity unusually high, compliance should be checked, interactions with other drugs or food considered and the imatinib blood levels determined. 


Challenges remaining and requiring new modes of cooperation concern geographic variations and demographics, quality controlled outcome of CML for international comparability, the availability of standardized diagnostics Europe-wide and globally, the role of TK inhibitor trough levels for response and outcome, and the provision of continued information and communication to all players in the field. In order to address these topics, a public-private partnership between the CML members of ELN and Novartis Oncology Europe has been initiated: the European Treatment and Outcome Study (EUTOS) for CML (Fig. 14).


The goals of this cooperation are expansion of the European CML registry, standardized molecular monitoring on an international basis, pharmacological monitoring and the spread of excellence. The contract was signed between the University of Heidelberg as legal representative of the ELN and Novartis in June 2007.

In summary, leukemias are rare diseases, the investigation into which requires multicenter activities, study groups and networking. The ELN integrates leukemia research and trial groups across Europe. Progress with CML continues to promote European integration (EUTOS for CML). Median survival with CML is now expected at 25 years. The main treatment options for CML are TK inhibition and allo-SCT. Treatment optimization trials are ongoing worldwide. Looking at the speed of current progress, the prospects for a cure of CML, and possibly other forms of leukemia, are good.


1. Virchow R. Weißes Blut (Leukämie). Archiv für path Anat. 1847;1:563.

2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497-1501.

3. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-554.

4. Daley GQ, van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.

5. Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344:251-253.

6. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Medic. 1996;2:561-566.

7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.

8. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.

9. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321-1331.

10. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood. 2007;109:4686-4692.

11. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.

12. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200-1206.

13. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112:1005-1012.

14. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib (AMN107), a novel, highly active, selective BCR-ABL tyrosine kinase inhibitor in patients with Philadelphia-Chromosome (Ph) positive chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) who are resistant to imatinib mesylate therapy. N Engl J Med. 2006;2542-2551.

15. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.

16. Sanz MA, Grimwade D, Tallman MS, et al. Guidelines on the management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2008;prepublished online September 23,2008.

17. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370:342-350.

Volume 1, Number 2

Download PDF version

doi 10.3205/ctt-2008-en-000015.01
Submitted 29 September 2008
Accepted 10 October 2008
Published 02 December 2008

Back to the list